Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Varenicline For Smokers In Recovery From Alcohol Dependence

This study has been completed.
Information provided by:
Mayo Clinic Identifier:
First received: March 19, 2010
Last updated: April 15, 2011
Last verified: April 2011
Results First Received: October 28, 2010  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Tobacco Abstinence
Intervention: Drug: Varenicline

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment began on 04/14/2008 and finished on 08/28/2008. Recruitment was in the general community of Rochester, Minnesota

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All potential participants consenting to enrollment completed a series of screening questionnaires. The questionnaires included demographic information, alcohol and smoking history, the the Center for Epidemiological Studies–Depressed Mood Scale, DAST-20, medical history and physical exam.

Reporting Groups
Varenicline Everyone on study received Varenicline (2 mg/day) daily for 12 weeks

Participant Flow:   Overall Study
Withdrawal by Subject                7 
Lost to Follow-up                2 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Varenicline Everyone on study received Varenicline (2 mg/day) daily for 12 weeks

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   32 
>=65 years   0 
[Units: Years]
Mean (Standard Deviation)
 42.9  (10.5) 
[Units: Participants]
Female   10 
Male   22 
Region of Enrollment 
[Units: Participants]
United States   32 
cigarettes per day [1] 
[Units: Cigarettes per day]
Mean (Standard Deviation)
 20.3  (5.0) 
[1] Self reported average number of cigarettes smoked per day over the preceding 6 months prior to study enrollment.
Duration of alcohol recovery [1] 
[Units: Months]
Median (Full Range)
 (6 to 217) 
[1] Self reported number of months in recovery from alcohol dependence prior to study enrollment.

  Outcome Measures

1.  Primary:   Biochemically Confirmed Abstinence From Smoking   [ Time Frame: 12 weeks from start of medication ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: J Taylor Hays. MD
Organization: Mayo Clinic
phone: 507-266-1944

Publications of Results:

Responsible Party: James Taylor Hays, MD, Mayo Clinic Identifier: NCT01092702     History of Changes
Other Study ID Numbers: 08-00672
Study First Received: March 19, 2010
Results First Received: October 28, 2010
Last Updated: April 15, 2011